Bird flu outbreak effects go beyond sick workers — 1.8 million dead chickens to affect consumers

Category: Health

The outbreak of bird flu in Colorado has sickened farmworkers, leading to a decrease in egg supplies and a potential rise in prices. Large producers are taking measures to maintain egg availability, but consumers may still experience price increases.

Keywords: bird flu, Colorado, egg supplies, price increase, farmworkers

Source: 9News.com KUSA

Update At: 7/17/2024

Related Sources

FDA approves blood test for colorectal cancer screening among average-risk adults in the US

The FDA has approved the Shield blood test for colorectal cancer screening in average-risk adults aged 45 and older, marking the first blood test approved as a primary screening option. This test aims to increase screening rates and early detection, potentially saving lives. It has shown an accuracy rate comparable to existing stool tests and is expected to be commercially available soon.

CNN

F.D.A. Approves Blood Test for Colon Cancer Detection

The Shield blood test by Guardant Health detects 83% of colorectal cancers but only 13% of dangerous polyps, making it less effective than colonoscopies. Approved by the FDA for individuals aged 45 and over, it aims to increase screening rates for colorectal cancer, which is the second leading cause of cancer-related deaths in the U.S. Despite its limitations, the test offers a simpler alternative to traditional screening methods.

The New York Times

In a big step for liquid biopsy, FDA approves a blood screening test for colorectal cancer

The FDA approved a blood test called Shield by Guardant Health for detecting colon cancer, aiming to improve early detection despite being less effective than colonoscopy. Many individuals avoid colonoscopies, highlighting the need for alternative screening methods.

STAT

FDA approves blood-based cancer test in medical breakthrough

Guardant Health's blood test, Shield, received FDA approval for colorectal cancer screening, potentially allowing Medicare coverage for older adults. The test, previously available as a laboratory-developed test, is more convenient than traditional feces-based tests and aims to reach over 50 million unscreened individuals. Shield detected 83% of colorectal cancers, while the stool test Cologuard had a 92.3% sensitivity rate.

New York Post

Blood test for colon cancer screening is approved by US regulators

The FDA has approved the Shield test, a noninvasive blood test for colon cancer screening in adults aged 45 and older. While not a replacement for colonoscopies, it offers a new option for those at average risk. The test detects DNA fragments from tumor cells and precancerous growths, but misses 17% of cancers. The approval is expected to enhance insurance coverage for the test, which costs $895 out-of-pocket.

AP News

FDA approves new blood test to screen for colon cancer

The FDA approved Guardant Health's blood test, Shield, for colon cancer screening, which could increase screening rates. While it is not a replacement for colonoscopies, it is expected to be more accessible with insurance coverage. The test is 83% effective in detecting colorectal cancers but primarily identifies later-stage cancers. A positive result still requires a follow-up colonoscopy for confirmation. The approval comes amid rising colon cancer rates in younger populations, highlighting the need for improved screening methods.

NBC News

Guardant Health Shares Rise 7% After FDA Approves Its Blood Test For Colon Cancers

Guardant Health's shares surged 7% after FDA approval of its blood test, Shield, for colon cancer screening in adults 45 and older. This test aims to increase screening rates as many eligible Americans avoid traditional methods like colonoscopies due to their invasive nature. Shield is the first FDA-approved blood test for primary colon cancer screening and is covered by Medicare. Despite its effectiveness, screening rates remain below the national goal.

Forbes

FDA approves new blood test to detect colon cancer

The FDA approved Guardant Health's blood test Shield for colon cancer screening, which is expected to increase accessibility and insurance coverage. While effective in detecting later-stage cancers, it has limitations in identifying precancerous growths compared to traditional methods like colonoscopies. The test is approved for individuals 45 and older at average risk, aiming to improve screening rates and reduce mortality from colorectal cancer.

Popular Science

FDA approves blood test to detect colon cancer for those at 'average risk'

The FDA has approved the Shield blood test for colorectal cancer screening in individuals aged 45 and older with average risk. While it offers a less invasive alternative to colonoscopies, it has a higher false positive rate and lower detection rates for large polyps. The test detects DNA from tumors in blood samples and aims to improve screening rates for colorectal cancer.

ABC News - Breaking News, Latest News and Videos

A new blood test for colon cancer just got approved by the FDA

The FDA has approved Guardant Health's Shield test, a new blood test for colorectal cancer screening in adults over 45, marking it as the first blood test to be recognized as a primary screening option for CRC. The test detects cancer signals from DNA in the bloodstream, showing 83% sensitivity for colorectal cancers. While not as effective as colonoscopies, it offers a less invasive alternative for those hesitant about traditional screenings.

Quartz